Alembic Pharma (ALPM) exhibited in-line revenue with a slight miss on EBITDA/PAT for the quarter. While ex-US export growth was strong for the quarter, it was offset by moderate YoY growth in domestic ...
Alembic Pharmaceuticals was hit with a patent infringement lawsuit on Dec. 19 in New York Eastern District Court over its planned generic version of the glaucoma treatment LUMIGAN®. The action, ...
Alembic Pharmaceuticals was sued for patent infringement on Dec. 19 in New York Eastern District Court for seeking to market a generic version of glaucoma treatment Lumigan. The action, brought by ...
Drugmaker Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Travoprost Ophthalmic Solution ...
Alembic Pharmaceuticals Limited (Alembic), a vertically integrated research and development pharmaceutical company, announced that it has received final approval from the US Food & Drug Administration ...
Alembic Pharmaceuticals Limited (Alembic), a vertically integrated research and development pharmaceutical company, announced that it has received final approval from the US Food & Drug Administration ...
International consultancy Accenture announced last week that it had invested in AI startup Alembic, kickstarting a partnership that will leverage the technology to better measure the effectiveness of ...
Accenture (ACN) announced an investment in Alembic, an AI-powered causal marketing intelligence platform. As part of the investment, the companies are entering into a strategic partnership to help ...
NEW YORK & SAN FRANCISCO - Accenture (NYSE:ACN) announced Monday it has invested in Alembic through its Accenture Ventures arm and formed a strategic partnership with the AI-powered causal marketing ...
Accenture (NYSE: ACN) has invested, through Accenture Ventures, in Alembic, a leading AI-powered causal marketing intelligence platform that can determine which marketing campaigns deliver a return on ...
Led by Prysm Capital and Accenture with participation from Silver Lake Waterman, Liquid 2 Ventures, NextEquity, Friends & Family Capital, and WndrCo, this round positions Alembic among the top AI labs ...
Alembic Technologies raises $145M and buys an Nvidia-powered supercomputer to accelerate ‘causal AI’
Causal artificial intelligence startup Alembic Technologies Inc. said today it has raised $145 million in a Series B growth round that increases its valuation almost 16-fold. It’s using a big chunk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results